Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-09-23 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CLO & Secretary) |
S | Common Stock | D | 2000 | $99.60 - $99.60 | $199,201 |
| 2024-09-23 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CLO & Secretary) |
M | Common Stock | A | 2000 | $52.27 - $52.27 | $104,540 |
| 2024-09-20 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
S | Common Stock | D | 1275 | $103.86 - $103.98 | $132,518 |
| 2024-09-20 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(President & COO) |
S | Common Stock | D | 16047 | $100.05 - $104.10 | $1,642,357 |
| 2024-09-20 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(President & COO) |
M | Common Stock | A | 14754 | $49.99 - $52.84 | $764,276 |
| 2024-09-17 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
M | Common Stock | A | 1486 | $57.22 - $80.72 | $118,328 |
| 2024-09-16 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(President & COO) |
M | Common Stock | A | 5774 | $49.99 - $60.94 | $337,695 |
| 2024-09-16 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(President & COO) |
F | Common Stock | D | 3214 | $105.00 - $105.00 | $337,470 |
| 2024-08-28 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
M | Common Stock | A | 753 | $57.22 - $70.04 | $50,085 |
| 2024-08-28 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CLO & Secretary) |
S | Common Stock | D | 1500 | $106.39 - $106.39 | $159,590 |
| 2024-08-28 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CLO & Secretary) |
M | Common Stock | A | 1500 | $52.27 - $52.27 | $78,405 |
| 2024-08-22 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(President & COO) |
S | Common Stock | D | 18858 | $104.09 - $106.32 | $1,986,417 |
| 2024-08-08 | LIGAND PHARMACEUTICALS INC | Davis Todd C
(Chief Executive Officer) |
P | Common Stock | A | 2500 | $97.39 - $97.39 | $243,480 |
| 2024-06-28 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(Chief Legal Officer &) |
J | Common Stock | A | 329 | $60.71 - $60.71 | $19,972 |
| 2024-06-28 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(President & Chief Operating) |
J | Common Stock | A | 350 | $60.71 - $60.71 | $21,247 |
| 2024-06-28 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
J | Common Stock | A | 267 | $60.71 - $60.71 | $16,208 |
| 2024-06-28 | LIGAND PHARMACEUTICALS INC | Davis Todd C
(Chief Executive Officer) |
J | Common Stock | A | 350 | $60.71 - $60.71 | $21,247 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | Sabba Stephen L
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | Zimmermann Martine
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | Haas Jason
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | Gray Nancy Ryan
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
| 2024-06-14 | LIGAND PHARMACEUTICALS INC | Aryeh Jason
(Director) |
A | Common Stock | A | 1252 | $0.00 - $0.00 | $0 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |